Endo (NDOI) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenues were $427 million, down 6% year-over-year, mainly due to competitive pressures in generics and sterile injectables, partially offset by branded segment growth, especially XIAFLEX®.

• Adjusted EBITDA rose 6% year-over-year to $151 million, reflecting improved gross margin and lower operating expenses.

• Net leverage improved to 3.3x, aided by strong cash generation, reduced debt, and term loan repricing.

• Net loss for Q3 2024 was $233 million, compared to a $28 million loss in Q3 2023, primarily due to fresh start accounting.

• Emerged from bankruptcy in April 2024, with new equity issued to creditors and $2.5 billion in new debt raised to fund settlements and operations.

Financial highlights

• Adjusted gross margin rose to 67.4% from 63.6% year-over-year, driven by favorable product mix and manufacturing productivity.

• Adjusted net income was $62 million, down from $131 million in Q3 2023, due to higher interest and tax expenses.

• Unrestricted cash at quarter-end was $368 million, up from $294 million at the end of Q2 2024.

• Net cash from operating activities was $12 million in Q3 2024, impacted by escrowed professional fee payments.

• Repriced $1.5 billion term loan, reducing interest rate by 50 basis points and saving $8 million annually.

Outlook and guidance

• Full-year 2024 revenue guidance reaffirmed at $1,720–$1,780 million and adjusted EBITDA at $635–$655 million.

• Segment revenue guidance: Branded $875–$905 million, Sterile Injectables $350–$370 million, Generics $430–$440 million, International $65–$67 million.

• Adjusted gross margin for 2024 expected to remain at ~67%; Q4 margin to be slightly lower due to product mix.

• On track to grow total company revenues in 2025; detailed 2025 guidance to be provided with year-end results.

• Liquidity supported by $368 million in cash and a $400 million undrawn revolving credit facility.